



QuikFlo announces private placement

Calgary, Alberta, March 21, 2016 – QuikFlo Health Inc. ("QuikFlo" or the "Company") (TSXV:QF)(FRANKFURT:1QF) announces that the Company is currently undertaking a non-brokered private placement of up to \$500,000, subject to regulatory approval. The Company is offering up to 3,333,333 units at a price of \$0.15 per unit, with each unit consisting of one common share and one share purchase warrant (a "Warrant") entitling the holder to purchase one additional common share for \$0.25 for a period of 18 months from closing. Proceeds will be used for general working capital and the ongoing development of QuikFlo's stroke diagnostic software tool.

This private placement is non brokered, but the Company will pay qualified finders a commission of 8% in cash and 8% in finders' warrants on the same terms as the Warrants.

About QuikFlo

QuikFlo is a medical software company developing innovative solutions for the analysis of medical images. Our primary focus is on improving outcomes for stroke patients, where existing time delays are solvable through more efficient triage based on rapid, accurate analysis of medical images.

Further Information

For further information relating to the Company or this release please visit www.sedar.com, www.quikflohealth.com, or contact Vinny Jindal, President and CEO at 646.526.9628 or Investor Relations for the Company at 647.980.7541.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary and Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. Forward-looking statements are provided for the purpose of providing information about the current expectations and plans of management of the Company relating

to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although management of the Company believes that the expectations and assumptions on which such forward looking statements and information are based are currently reasonable, actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to identify and complete suitable acquisitions to further the Company's growth, the suitability of the key members of ongoing management and the board of directors, the biomedical and technology sectors in general such as operational risks in development, research and regulatory delays or changes in plans with respect to research projects or capital expenditures; the uncertainty of the market; the uncertainty of estimates and projections relating to costs and expenses; health, safety and environmental risks; marketing and commercialization; loss of markets; competition; ability to access sufficient capital; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws, and government regulations, and other risks identified in the recent information circular available on www.sedar.com. Accordingly, readers should not place undue reliance on the forward-looking statements, timelines and information contained in this news release.

No undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.